Healthcare-focused investment firm OrbiMed Advisors completely sold off its stake in Pfizer (PFE), according to a quarterly disclosure filed on August 14, 2026. The filing, which reflects trades made during the second quarter ending June 30, 2026, revealed the sale of 1.95 million shares, previously valued at approximately $54.66 million. This holding had accounted for about 1.08% of OrbiMed's reported portfolio.
Investors should note that 13F filings are submitted to the SEC up to 45 days after a quarter ends, so these trades do not reflect the firm's current-day positions. During the second quarter, Pfizer raised its full-year 2026 revenue guidance, driven by strong performance from non-COVID products which helped to offset declining sales from its COVID-19 treatments.